Department of Medicine

University of Pittsburgh

Margaret V. Ragni, MD, MPH
photo

Professor of Medicine, Division Hematology/Oncology

Director, Hemophilia Center of Western PA
Office: Hemophilia Center WPA,3636 Blvd of the Allies
Pittsburgh, PA 15213
 
Phone: 412-209-7288
Fax: 412-209-7281
E-mail: ragni@dom.pitt.edu
Education
BS, Chatham College, Pittsburgh, PA, 1971
MD, University Pittsburgh School of Medicine, 1975
MPH, Graduate School of Public Health, 1993
Training
Medical Internship/ Residency, University of Pittsburgh Medical Center, 1978
Fellowship, Hematology, University of Pittsburgh School of Medicine, 1981
Coagulation Hematology, Central Blood Bank, Pittsburgh, PA, 1982
Area of Specialization/Research Interest  
Epidemiology of HIV/HCV infection in hemophilia and liver disease progression, liver transplantation
Immunogenetics of hemophilia inhibitors and prevention of inhibitors
Dendritic cell tolerance in hemophilia mouse and inhibitor formation
Genetics and clinical phenotype of VWD
New treatments for Von Willebrand Disease
Thrombophilia and duration/management anticoagulation
F.VIII, VWF, F.IX and cardiovascular risk in aging hemophiliacs
Bleeding disorders in women
VWD in children
 
Profile
Dr. Ragni is Professor of Medicine and Clinical Translational Science, Division Hematology/Oncology and Director, Hemophilia Center of Western PA. She is PI on a T35 student research grant and collaborates on an NHLBI genotype-phenotypes von Willebrand study; an NIAID-funded organ transplantation in HIV, an NHLBI-funded hemophilia gene transfer, and an NHLBI-funded Transfusion Medicine/Hemostasis clinical trials network. She is a member of the Medical and Scientific Advisory Board, National Hemophilia Foundation and of the NHLBI Hemostasis & Thrombosis study section. She chaired the Hemophilia/VWD Subcommittee of the NHLBI State of the Science Symposium 2009, developing four clinical trial concepts, three submitted. She is a member of the ASH Development Committee, Contributing Editor to The Hemologist, and on the Editorial Board of Haemophilia. She was nominated to FDA Blood Products Advisory Committee and serves as Co-chair, Hemostasis Thrombosis Research Society Research Committee.
Recent Grants
Title: R01 Phase I/II AAV - 2/8 Gene Transfer IX in Hemophilia B
Role: Local PI
Amount: $19,906 direct
Funding Agency: NHLBI, St. Jude
Start Year: 2010
End Year: 2012
Title: IL-II in DDAVP Unresponsive Patients
Role: PI
Amount: $25,000 direct
Funding Agency: VMI (Pitt)
Start Year: 2010
End Year: 2011
Title: B2B Bench to Bedside Hemolysis Activation SCD
Role: Co-Investigator
Amount: $102,570 direct
Funding Agency: NHLBI
Start Year: 2010
End Year: 2011
Title: Baxter Phase III Recombinant VWF
Role: Local PI
Amount: $32,567 direct
Funding Agency: Baxter
Start Year: 2009
End Year: 2011
Title: Gene IX AAV, Transfer Under Immunomodulation
Role: Local PI
Amount: $433,512 direct
Funding Agency: CHOP, U Penn
Start Year: 2009
End Year: 2011
Title: Inhibitor Eradication in Mouse Model Hemophilia A
Role: Co-PI
Amount: $200,000 direct
Funding Agency: Baxter
Start Year: 2008
End Year: 2011
Title: 5-P01 Molecular and Clinical Understanding of Von Willebrand Disease
Role: Co-Investigator, local PI on Multicenter Grant
Amount: $132,730 direct
Funding Agency: NHLBI - Program Project Grant Specialized Center of Clinically Oriented Research
Start Year: 2005
End Year: 2011
Title: 2-T35 Training Students in Biomedical Research in Hematology
Role: PI
Amount: $198,000 direct
Funding Agency: NHLBI
Start Year: 2005
End Year: 2015
Title: 4-U01 Solid Organ Transplantation in HIV: Multi-Site Study
Role: Local PI on Multicenter Study
Amount: $1,007,763 direct
Funding Agency: NIAID
Start Year: 2003
End Year: 2012
Title: 2-U01 Transfusion Medicine Hemostasis Clinical Trials Network
Role: Co-Investigator
Amount: $1,874,179 direct
Funding Agency: NHLBI
Start Year: 2002
End Year: 2012
For Pub Med search results, click here.